<DOC>
	<DOCNO>NCT00840489</DOCNO>
	<brief_summary>The rate sustain virological response course standard antiviral therapy ( peg-interferon plus ribavirin ) patient chronic hepatitis C infect genotype 1 advanced fibrosis ( &gt; F2 ) rather low . Monotherapy ribavirin reduces ALT level necroinflammatory liver activity half non-responders standard antiviral therapy , without change liver fibrosis viremia . Such beneficial effect seem mainly due immunomodulatory effect ribavirin . Portal pressure , measure HVPG , lower patient chronic hepatitis C advance fibrosis end-of-treatment response peg-interferon plus ribavirin . Portal pressure reduction set relates reduction necroinflammatory liver activity , fibrosis amelioration . We hypothesize monotherapy ribavirin reduces portal pressure hepatitis C patient advance fibrosis mean immunomodulatory anti-inflammatory effect , could constitute alternative non-responders standard antiviral treatment . Portal pressure measurement become validated surrogate outcome measure chronic liver disease , since decrease portal pressure show consistent improvement survival clinical outcome , complication portal hypertension . The primary aim study investigate whether ribavirin monotherapy slow progression advance chronic liver disease hepatitis C assess reduction HVPG .</brief_summary>
	<brief_title>Efficacy Long-term Ribavirin Non-responders With Chronic Hepatitis C Advanced Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>HCV RNA serum AST/ALT great upper limit normal range HVPG &gt; 5 mm Hg Nonresponse contraindication standard course antiviral therapy Active alcoholism HIV infection Serum creatinine &gt; 1.2 mg/dl , hemoglobin &lt; 11 g/dl , hemolysis , symptomatic ischemic heart disease cerebrovascular disease Decompensated chronic liver disease Pregnancy Hypersensitivity drug study Severe concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>